GPX4 and neoplasm: In the LAR subtype of TNBC, elevated GPX4 levels enhance anti-tumor immunity; however, inhibiting GPX4 induces ferroptosis, particularly when combined with anti-PD1 therapy, leading to greater efficacy compared to monotherapy.